Table 2. Leaders in the number of public-private partnerships. The NIH and European Commission took the top positions with respect to the number of disclosed public-private partnerships (PPPs) in 2012. The U.K.'s GlaxoSmithKline plc took the top spot on the company side, whereas Sanofi and Pfizer Inc. shared the second spot. Excludes deals that only involved IP transfer.

Source: BioCentury Archives

Institute

Number of PPPs

NIH (includes the National Cancer Institute and National Institute for Allergy and Infectious Diseases)

17

European Commission (via the Seventh Framework Program)

16

BGI

9

Bill & Melinda Gates Foundation

8

Agency for Science, Technology and Research (A*STAR)

7

Harvard University

7

Innovative Medicines Initiative

7

University College London

7

The University of Texas (includes The University of Texas Medical Branch, The University of Texas MD Anderson Cancer Center and The University of Texas Southwestern Medical Center)

7

Company

Number of PPPs

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK)

15

Pfizer Inc. (NYSE:PFE)

11

Sanofi (Euronext:SAN; NYSE:SNY)

11

AstraZeneca plc (LSE:AZN; NYSE:AZN)

10

Johnson & Johnson (NYSE:JNJ)

10